11 June 2020 | News
For the development and manufacturing of its next-generation immune checkpoint blockade
Image credit- shutterstock.com
Korean firm PharmAbcine Inc. has entered into a strategic partnership with Thermo Fisher Scientific for the development and manufacturing of PMC-309, a next-generation immune checkpoint blockade to treat cancer.
PMC-309 is a novel fully human monoclonal IgG targeting unique epitope of human VISTA (V-domain Ig suppressor of T cell activation) primarily expressed on MDSC (myeloid-derived suppressor cells). It can provide a promising immunotherapeutic strategy to improve the antitumor activity through inhibition of VISTA-positive immunosuppressive cell activities.
The drug product of PMC-309 for clinical trial will be developed at Thermo Fisher's Princeton, NJ, USA and the Brisbane's site in Australia will facilitate for the drug substances. PharmAbcine is planning to initiate IND enabling studies this year and submit global IND in 2021.